First Allied Advisory Services’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

First Allied Advisory Services’s Portfolio NAVB Stock Details NAVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	–	Sell	-628	Closed	-$18K	–	1131
2014 Q2	$18K	Hold	628	–	–	﹤0.01%	973
2014 Q1	$24K	Hold	628	–	–	﹤0.01%	997
2013 Q4	$26K	Hold	628	–	–	﹤0.01%	941
2013 Q3	$33K	Sell	628 -3,123	-83%	-$182K	﹤0.01%	995
2013 Q2	$200K	Buy	+3,751	New	+$187K	0.02%	838

Other funds holding NAVB

Platinum Management New York $16.4M AUM 30.38% 1-Year Est. Return

Commerzbank Aktiengesellschaft Frankfurt, Germany $5B AUM 26.58% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Nomura Holdings Tokyo, Japan $85.4B AUM 91.09% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

First Allied Advisory Services's NAVB Position: Q3 2014 in Review

First Allied Advisory Services sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q3 2014, closing a stake of 628 shares — an estimated $18K sold.

First Allied Advisory Services first reported a position in NAVB in Q2 2013 and held it in 5 quarters. The position peaked at $200K in Q2 2013. 81 funds tracked by Wall St. Rank hold NAVB as of Q3 2014.

First Allied Advisory Services reported no remaining Navidea Biopharmaceuticals Inc. position as of Q3 2014 after selling out during the quarter.
First Allied Advisory Services sold 628 Navidea Biopharmaceuticals Inc. shares in Q3 2014, an estimated $18K.
First Allied Advisory Services first reported a position in Navidea Biopharmaceuticals Inc. in Q2 2013 and held it in 5 quarters.
First Allied Advisory Services's Navidea Biopharmaceuticals Inc. position peaked at $200K in Q2 2013.
81 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q3 2014.

Based on First Allied Advisory Services's 13F filing for Q3 2014, filed 12 Nov 2014.